Zhengye Biotechnology Holding (ZYBT)

The company offers vaccines for a range of animals, including swine, cattle, goats, sheep, poultry, waterfowl, and pets. This product breadth allows Zhengye Biotechnology to serve multiple parts of the animal husbandry market rather than relying on a single species category. Swine vaccines represent its largest source of revenue, followed by poultry vaccines and other animal vaccine products. That sales mix reflects the importance of pig farming and poultry production within China’s broader protein supply chain.

Zhengye Biotechnology sells across various provincial regions in China and also exports to overseas markets such as Vietnam, Pakistan, and Egypt. Its operations are shaped by factors that affect the veterinary vaccine industry, including livestock population trends, disease outbreaks, farm biosecurity practices, government regulation, product approvals, and manufacturing quality standards.

For investors, ZYBT is tied to demand for preventive animal healthcare and the modernization of livestock production. The company’s competitive position depends on vaccine efficacy, production capacity, distribution reach, pricing, and its ability to keep product offerings aligned with evolving disease risks in domestic and international markets.